Neoleukin therapeutics, inc. (AQXP)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue (Note 9)

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development (Note 6)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development (Note 7)

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development (Note 3)

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

40,998

-

32,840

30,518

29,278

28,382

24,176

21,729

16,113

15,799

18,198

19,834

20,766

18,079

14,505

12,209

8,906

7,599

0

0

0

General and administrative (Note 6)

19,844

18,826

18,086

12,190

14,081

15,835

18,080

17,210

16,416

14,852

13,210

11,745

10,055

9,263

7,598

6,679

6,022

5,541

5,368

5,125

5,033

4,296

3,396

2,799

2,088

1,777

0

0

0

Total operating expenses

77,371

70,959

67,903

23,584

45,466

57,624

68,856

65,729

57,414

51,119

46,050

42,263

39,333

37,645

31,774

28,408

22,135

21,340

23,566

24,959

25,799

22,375

17,902

15,009

10,994

9,376

0

0

0

Loss from operations

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net
Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Sale of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of derivative liabilities (Note 6(a))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

981

1,900

0

-

0

0

-

Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,884

2,004

2,124

0

-

0

0

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

451

0

0

0

-

0

0

0

Other income, net (Note 11)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

98

-24

-520

228

345

499

683

0

0

0

-

-

-

-

Other income (expenses)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Foreign exchange loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Other income, net (Note 7)

1,495

1,517

1,675

1,495

1,296

1,039

890

923

924

936

809

0

0

-

0

-

-

-

-

-

-

-1,652

-1,573

-1,554

-957

642

0

0

0

Net loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-19,475

-16,564

-11,951

-8,734

0

0

0

Income tax recovery (Note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Net loss

-75,876

-69,442

-66,228

-22,089

-19,170

-31,585

-42,966

-39,806

-56,490

-50,183

-45,159

-41,472

-38,607

-37,002

-31,421

-28,310

-22,159

-21,860

-24,288

-25,537

-26,211

-24,027

-19,303

-13,830

0

-

0

0

-

Basic

-

-

-

-

-

-

-

0.12

-

-

-

-0.59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

0.12

-

-

-

-0.59

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic

-

-

-

23,537

-

-

-

23,521

-

-

-

23,444

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

23,537

-

-

-

23,846

-

-

-

23,444

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion for liquidation preference on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accretion for share issuance costs on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Tax expense on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Total loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss per common stock - basic and diluted (Note 8)

-0.18

-

-2.26

-

-0.09

-

-0.64

-

-0.62

-

-0.50

-

-0.36

-0.48

-0.46

-0.63

-0.39

-0.26

-0.43

-0.44

-0.60

-0.37

-0.59

-0.51

-1.28

-17.51

-15.64

-7.89

-8.48

Basic and diluted weighted average number of common stock outstanding (Note 8)

49,168

-

26,185

-

23,537

-

23,537

-

23,480

-

23,464

-

23,423,150

23,459

17,690

17,212

17,211

17,274

11,841

10,723

10,711

10,150

10,695

10,675

3,148

301

301

301

301

Comprehensive loss:
Net loss

-75,876

-69,442

-66,228

-22,089

-19,170

-31,585

-42,966

-39,806

-56,490

-50,183

-45,159

-41,472

-38,607

-37,002

-31,421

-28,310

-22,159

-21,860

-24,288

-25,537

-26,211

-24,027

-19,303

-13,830

0

-

0

0

-

Other comprehensive income—unrealized gain on available-for-sale securities

-

-

-

-

-

70

103

203

181

99

-95

-277

-158

121

-11

68

-50

-286

13

15

0

-

0

0

-

-

-

-

-

Comprehensive loss

-75,876

-69,442

-66,228

-22,087

-19,146

-31,515

-42,863

-39,603

-56,309

-50,084

-45,254

-41,749

-38,765

-36,881

-31,432

-28,242

-22,209

-22,146

-24,292

-25,534

-26,208

-24,031

-19,468

-16,558

-11,946

-8,729

0

0

0